OMER News and Press, Omeros Corporation From 09/25/19

Omeros Corporation (Nasdaq: OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria ( i.e. , high levels of plasma proteins in the urine) and inflammation. The...

Omeros ( OMER +2% ) is up on below-average volume in response to positive data from a Phase 1 clinical trial evaluating addiction candidate OMS182399 in 47 healthy volunteers. More news on: Omeros Corporation, Healthcare stocks news, Stocks on the move, Read more ...

-- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- Omeros Corporation (Nasdaq: OMER) today announced positive results from its Phase 1 study with the lead compound in its OMS527 program. The OMS527 program is developing phosphodiesterase ...

– Omeros Remains On Track to Initiate the Submission Next Quarter – Omeros Corporation (Nasdaq: OMER) announced that the United States Food and Drug Administration (FDA) agreed with the company’s proposed schedule for the rolling review of the Biologics License...

-- The Company’s GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- Omeros Corporation (Nasdaq: OMER) today announced a new approach to cancer immunotherapy that targets inhibition of GPR174, a member of the family of G protein-co...

Omeros Corporation (Nasdaq: OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21 st Annual Global Investment Conference in New York next week. The presentation is scheduled for Tuesday, September 10, 2019 at 10:0...

The U.S. is by far the global leader in healthcare research, and the reason is that the government promotes the research and development of innovative drugs and devices through reimbursements to the physicians who purchase them. It's this very important drug payback system that confers a huge ad...

We closely follow high Short interest stocks because the group often times presents good trading opportunities and contrarian investment ideas with potentially significant mispricing opportunities. There are many ways to analyze Short interest data, in some ways it's a backwards looking indi...

"I am a man of simple tastes easily satisfied with the best ” ― Winston S. Churchill We continue our series of reviews of Q2 results at previously profiled small biotech concerns today, revisiting Omeros ( OMER ) after the company posted much better than expected quarter...

August 12, 2019 Palm Beach, FL – August 12, 2019 – Cellulite has been the bane of many women (and men too) for years, but the market is expected to rise significantly through 2026, industry reports project. One report said that the global cellulite treatment market...